GO:0000339 RNA cap binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0000339 RNA cap binding describes the molecular function of binding to the 7-methylguanosine (m7G) cap at the 5' end of RNA, a hallmark of RNA polymerase II transcripts.
• The nuclear cap-binding complex (CBC), composed of NCBP1 (CBP80) and NCBP2 (CBP20), is the primary protein complex that recognizes the m7G cap and couples it to splicing, export, and translation.
• Cap-binding proteins such as eIF4E and CBC regulate translation initiation and are targeted by cellular signaling pathways including mTOR and the integrated stress response.
• Decapping enzymes (DCP1/DCP2, NUDT16, and viral decapping proteins) remove the cap and are central to RNA turnover and quality control.
• Cap-related modifications and cap analogs are powerful tools for crosslinking, imaging, and therapeutic mRNA design.
• Dysregulation of cap binding is linked to cancer, neurodegeneration, and viral pathogenesis, making it a target for CRISPR-based functional studies.
Description
RNA cap binding (GO:0000339) is a molecular function defined as binding to a 7-methylguanosine (m7G) group or derivative located at the 5' end of an RNA molecule. This function is essential for the recognition and processing of RNA polymerase II transcripts, including messenger RNAs (mRNAs) and small nuclear RNAs (snRNAs). The m7G cap is added co-transcriptionally and serves as a molecular signature that distinguishes genuine 5' ends from internal RNA fragments, thereby influencing RNA stability, splicing, export, and translation. The primary proteins that execute RNA cap binding are the nuclear cap-binding complex (CBC), a heterodimer of NCBP1 (CBP80) and NCBP2 (CBP20), and the cytoplasmic cap-binding protein eIF4E, which is part of the translation initiation machinery. These proteins physically interact with the m7G cap and recruit additional factors that mediate downstream events. For example, CBC bound to the cap interacts with splicing factors and export receptors, while eIF4E recruits eIF4G and eIF4A to initiate translation. Understanding RNA cap binding is critical for researchers because it sits at the intersection of RNA processing, gene expression control, and disease. Mutations or dysregulation in cap-binding proteins can lead to developmental defects, cancer, and neurological disorders. Moreover, viral proteins often mimic or hijack cap-binding functions to evade host immunity, as seen with poxvirus and orf virus decapping enzymes. This article synthesizes authoritative QuickGO data and verified PubMed literature to provide a research-grade overview of GO:0000339, its mechanisms, key genes, and experimental approaches.
RNA cap binding At A Glance
| GO ID | GO:0000339 |
|---|---|
| GO term | RNA cap binding |
| Ontology | molecular_function |
| Synonym | binding to mRNA cap; mRNA cap binding; snRNA cap binding |
| Definition | Binding to a 7-methylguanosine (m7G) group or derivative located at the 5' end of an RNA molecule. |
| Major function | Recognition of the 5' m7G cap on RNA polymerase II transcripts, enabling downstream processing, export, translation, and turnover. |
| Key protein families | Cap-binding complex (CBC: NCBP1/NCBP2), eIF4E family, decapping enzymes (DCP2, NUDT16), viral decapping proteins. |
| Subcellular localization | Nucleus (CBC) and cytoplasm (eIF4E, decapping machinery). |
| Related processes | mRNA splicing, nuclear export, translation initiation, RNA decay, snRNA maturation. |
What Is GO:0000339?
RNA cap binding (GO:0000339) is the molecular function of selectively binding to a 7-methylguanosine (m7G) group or its derivative at the 5' end of an RNA molecule. This binding event is non-covalent and is typically mediated by aromatic stacking and hydrogen bonding interactions within a cap-binding pocket. The function is distinct from cap addition (capping enzyme activity) and cap removal (decapping), focusing solely on recognition and physical association with the cap structure.
Why Is RNA cap binding Important in Cell Biology?
RNA cap binding is a central node in post-transcriptional gene regulation. It determines how RNAs are recognized, processed, and translated, and it is a point of vulnerability for pathogens and disease. The m7G cap is a unique chemical mark that allows cells to distinguish self from non-self RNA and to coordinate the fate of thousands of transcripts. Consequently, proteins that bind the cap are essential for cell viability, and their dysfunction is associated with a range of human diseases, including cancer, neurodegeneration, and viral infections.
• RNA cap binding is required for efficient pre-mRNA splicing and polyadenylation, linking transcription to RNA processing.
• The CBC mediates nuclear export of mRNAs and snRNAs, influencing gene expression at a global level.
• eIF4E, a cytoplasmic cap-binding protein, is a rate-limiting factor for translation initiation and is regulated by mTOR signaling.
• Decapping enzymes that compete with cap-binding proteins control mRNA stability and quality control.
• Cap-binding proteins are targeted by viruses to evade host antiviral responses, as shown for orf virus decapping protein OV71.
• Mutations in cap-binding proteins can cause developmental disorders and are implicated in cancer progression.
• Cap analogs and photoactivatable probes enable precise mapping of RNA-protein interactions.
• Cap-related modifications such as m6Am influence binding to immune sensors like IFIT proteins.
• RNA cap binding is a potential therapeutic target for antiviral and anticancer strategies.
• CRISPR screens can identify genes that regulate cap binding and downstream translation.
What Happens During RNA cap binding?
Recognition of the m7G cap by the CBC
In simple terms: The cell puts a special tag on the front of new RNA, and a protein complex grabs it to start processing.
The nuclear cap-binding complex (CBC) is a heterodimer of NCBP1 (CBP80) and NCBP2 (CBP20) that specifically binds the m7G cap on nascent RNA polymerase II transcripts. NCBP2 contains a cap-binding pocket that stacks the methylated guanine, while NCBP1 provides a platform for protein-protein interactions. This binding occurs co-transcriptionally and is the first step in a series of events that couple transcription to RNA processing.
Coupling to splicing and 3' end processing
In simple terms: Once the cap is grabbed, the complex helps the RNA be cut and pasted into its final form.
CBC bound to the cap interacts with splicing factors and the polyadenylation machinery, enhancing the efficiency and accuracy of pre-mRNA splicing and 3' end formation. This coupling ensures that only properly capped transcripts are processed, providing a quality-control mechanism.
Nuclear export of capped RNAs
In simple terms: The cap-bound complex acts like a passport, helping the RNA leave the nucleus.
The CBC recruits export receptors such as NXF1 to facilitate the nuclear export of mRNAs and snRNAs. This export step is essential for the cytoplasmic functions of these RNAs and is directly linked to the cap-binding event.
Cytoplasmic translation initiation by eIF4E
In simple terms: In the cytoplasm, another cap-binding protein helps the RNA be translated into protein.
eIF4E binds the m7G cap and recruits eIF4G and eIF4A to form the translation initiation complex. This interaction is regulated by mTOR signaling and is a key control point for protein synthesis. The switch from CBC to eIF4E is a hallmark of the mRNA lifecycle.
Decapping and RNA turnover
In simple terms: When the RNA is no longer needed, the cap is removed to allow degradation.
Decapping enzymes such as DCP2 and NUDT16 remove the m7G cap, exposing the RNA to exonucleases. Viral decapping proteins like OV71 from orf virus also target the cap to evade host immunity. This process is tightly regulated and is influenced by cap modifications.
Key Genes Involved in GO:0000339 RNA cap binding
The following genes encode proteins that directly bind the RNA cap or regulate cap-binding events, as supported by the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| NCBP1 | Core subunit of the nuclear cap-binding complex (CBC); interacts with NCBP2 and other factors. | Essential for splicing, export, and cell viability; knockout causes early embryonic lethality. |
| NCBP2 | Cap-binding subunit of CBC; directly contacts the m7G cap. | Mutations affect cap binding and RNA processing; target for structural studies. |
| EIF4E | Cytoplasmic cap-binding protein; recruits translation initiation factors. | Overexpressed in many cancers; target of mTOR inhibitors. |
| EIF4G | Scaffold protein that binds eIF4E and ribosome; bridges cap to translation. | Modulates translation efficiency; studied in cap-dependent translation. |
| DCP2 | Catalytic subunit of the decapping complex; removes m7G cap. | Regulates mRNA stability; knockout affects RNA turnover. |
| DCP1A | Regulatory subunit of decapping complex; activates DCP2. | Involved in mRNA decay and P-body formation. |
| NUDT16 | Decapping enzyme for U8 snoRNA and other RNAs. | Role in snRNA processing and quality control. |
| IFIT1 | Interferon-induced protein that binds cap-related modifications. | Mediates antiviral response by recognizing non-self caps. |
| IFIT2 | Interferon-induced protein; binds RNA caps with specific modifications. | Contributes to antiviral restriction. |
| IFIT3 | Interferon-induced protein; modulates IFIT1/2 binding. | Regulates innate immune recognition of capped RNA. |
| DAP5 | Cap-independent translation factor; binds 5' UTR structures. | Studied in IRES-mediated translation. |
| FGF9 | Growth factor with 5' UTR that forms cap-independent translation elements. | Model for cap-independent translation. |
| OV71 | Viral decapping protein from orf virus. | Evades host immunity by removing cap. |
| NCBP3 | Auxiliary cap-binding protein; associates with CBC. | Modulates RNA export and stress responses. |
| EIF4A | RNA helicase recruited by eIF4E/eIF4G. | Required for translation initiation; target for inhibitors. |
| PABPC1 | Poly(A)-binding protein; interacts with eIF4G to circularize mRNA. | Enhances translation and mRNA stability. |
| RNMT | RNA guanine-7 methyltransferase; adds m7G cap. | Essential for cap formation; upstream of cap binding. |
| RNGTT | RNA guanylyltransferase; adds GMP to 5' end. | Required for cap synthesis. |
How Is RNA cap binding Regulated?
RNA cap binding is regulated at multiple levels. The availability of eIF4E is controlled by mTOR signaling, which phosphorylates 4E-BP proteins to release eIF4E for translation initiation. The integrated stress response (ISR) can also modulate cap-dependent translation by phosphorylating eIF2α. Cap modifications, such as m6Am, can alter binding affinity for proteins like IFIT1 and IFIT2, thereby influencing immune recognition. Additionally, the nuclear CBC is regulated by its interaction with NCBP3 and other factors that respond to cellular stress. Decapping activity is controlled by the recruitment of DCP1/DCP2 to specific mRNAs and by viral proteins that mimic or inhibit decapping.
RNA cap binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| EIF4E | Cancer (overexpression promotes oncogenic translation) | Knockout or overexpression in cancer cell lines; xenograft models. |
| NCBP1 | Developmental defects and cancer (essential for splicing/export) | Conditional knockout in mouse models; CRISPR KO in human cells. |
| NCBP2 | Ribosomopathy-like phenotypes (impaired RNA processing) | Point mutations in cap-binding pocket; knock-in mice. |
| DCP2 | Neurodegeneration (defective mRNA decay) | Knockout in neuronal cell lines; CRISPR KO in iPSC-derived neurons. |
| IFIT1 | Viral susceptibility (impaired interferon response) | Knockout in immune cells; viral infection models. |
Cancer
Dysregulation of cap binding is frequently observed in cancer. Overexpression of eIF4E enhances translation of oncogenic mRNAs and is associated with poor prognosis in several cancers. The CBC subunit NCBP1 is also implicated in tumorigenesis through its role in splicing and export of oncogenic transcripts. Targeting cap-binding proteins with inhibitors or CRISPR knockout is a promising therapeutic strategy.
Neurodegeneration
Defects in RNA processing and translation are linked to neurodegenerative diseases. Mutations in cap-binding proteins or their regulators can impair neuronal survival. For example, altered eIF4E activity has been observed in models of Alzheimer's disease and amyotrophic lateral sclerosis. The CBC is also important for the processing of neuronal mRNAs.
Viral infections
Viruses often hijack or mimic cap-binding proteins to evade host immunity. Orf virus encodes OV71, a decapping enzyme that removes the cap from host mRNAs, thereby suppressing antiviral responses. Other viruses, such as poxviruses, also encode decapping enzymes. Understanding these interactions can inform antiviral drug development.
From RNA cap binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of NCBP1 affect global splicing and export? | CRISPR knockout of NCBP1 in HEK293T or HeLa cells followed by RNA-seq. |
| How does a point mutation in the cap-binding pocket of NCBP2 alter RNA binding? | CRISPR knock-in of specific point mutations in NCBP2; cap-binding assays. |
| Can overexpression of eIF4E drive oncogenic translation? | Stable overexpression of eIF4E in cancer cell lines; polysome profiling. |
| What is the role of DCP2 in mRNA stability? | CRISPR knockout of DCP2; RNA stability assays and RNA-seq. |
| How do viral decapping proteins like OV71 interact with host RNA? | Knock-in of OV71 into viral or host genomes; crosslinking and immunoprecipitation. |
| Does m6Am modification affect IFIT1 binding? | Point mutations in cap-modifying enzymes; in vitro binding assays. |
How to Study the RNA cap binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Ribo-seq | Ribosome occupancy and translation efficiency | Global translation changes after eIF4E knockout. |
| RNA-seq | Gene expression, splicing, and stability | Effects of CBC depletion on RNA processing. |
| CLIP-seq | Direct RNA binding sites of proteins | Mapping CBC and eIF4E binding across the transcriptome. |
| AP-MS | Protein-protein interactions | Identifying CBC interactors and decapping complex components. |
| Photoactivatable crosslinking | Covalent capture of RNA-protein interactions | Mapping cap-binding pockets with cap analogs. |
| In vitro binding assays | Binding affinity (Kd) for cap analogs | Characterizing mutant cap-binding proteins. |
| Polysome profiling | Distribution of mRNAs in translation gradients | Assessing cap-dependent translation initiation. |
| CRISPR screens | Gene essentiality and synthetic lethality | Identifying regulators of cap binding and translation. |
Ribo-seq and polysome profiling
Ribo-seq measures ribosome occupancy on mRNAs and can reveal changes in translation efficiency upon modulation of cap-binding proteins. Polysome profiling separates actively translated mRNAs from untranslated pools, providing a global view of cap-dependent translation.
RNA-seq and CLIP-seq
RNA-seq identifies changes in splicing, export, and stability caused by loss of cap-binding proteins. CLIP-seq (crosslinking and immunoprecipitation followed by sequencing) maps direct RNA binding sites of proteins like CBC and eIF4E at nucleotide resolution.
Proteomics and interactomics
Affinity purification coupled to mass spectrometry (AP-MS) identifies protein-protein interactions of cap-binding complexes. Photoactivatable cap analogs enable covalent crosslinking of cap-binding proteins for identification and mapping.
Structural biology and imaging
X-ray crystallography and cryo-EM provide high-resolution structures of cap-binding proteins bound to m7G cap analogs. Fluorescence microscopy can visualize the subcellular localization of cap-binding proteins and their dynamics.
How CRISPR Can Be Used to Study GO:0000339 RNA cap binding
Knockout
CRISPR knockout of cap-binding genes such as NCBP1, NCBP2, or EIF4E can reveal their essential roles in RNA processing and translation. For example, NCBP1 knockout in human cells causes defects in splicing and export, leading to cell death. EIF4E knockout reduces global translation and inhibits cancer cell proliferation. These models are valuable for studying gene function and for target validation.
Point Mutation
Point mutations in the cap-binding pocket of NCBP2 or EIF4E can be introduced using CRISPR base editing or homology-directed repair. Such mutations allow researchers to dissect the specific contribution of cap binding to protein function without completely abolishing protein expression. For instance, mutating key aromatic residues in eIF4E that stack the m7G cap abolishes translation initiation.
Knock-in
Knock-in of epitope tags (e.g., FLAG, HA) or fluorescent proteins into endogenous cap-binding genes enables real-time imaging and biochemical purification. Tagged NCBP1 or eIF4E can be used for CLIP-seq, AP-MS, and live-cell imaging to study dynamics and interactions. Knock-in of disease-associated mutations can model human disorders in cell lines or mice.
Overexpression
Overexpression of cap-binding proteins like eIF4E or NCBP1 can drive oncogenic transformation and alter global translation. Stable cell lines overexpressing these genes are used to study their gain-of-function effects and to test targeted inhibitors. Overexpression of viral decapping proteins such as OV71 can suppress host immunity and is used to study viral evasion mechanisms.
How EDITGENE Supports RNA cap binding Research
Researchers studying RNA cap binding-related genes often need to determine whether a candidate gene is causally involved in RNA processing, translation, or disease. CRISPR-based models provide a robust way to manipulate these genes with precision, enabling loss-of-function, gain-of-function, and disease-relevant mutation studies. EDITGENE offers a comprehensive suite of services to accelerate such research.
Contact EDITGENE today to design your custom CRISPR model for RNA cap binding research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| EIF4E2 Knockout HEK293 Cell Line | EDJ-KQ792 | Human | 9470 | Details Get a Quote |
| LARP1 Knockout HEK293 Cell Line | EDJ-KQ2425 | Human | 23367 | Details Get a Quote |
| EIF4G3 Knockout HEK293 Cell Line | EDJ-KQ6321 | Human | 8672 | Details Get a Quote |
| IFIT5 Knockout HEK293 Cell Line | EDJ-KQ8146 | Human | 24138 | Details Get a Quote |
| LARP1B Knockout HEK293 Cell Line | EDJ-KQ14025 | Human | 55132 | Details Get a Quote |
| NCBP2L Knockout HEK293 Cell Line | EDJ-KQ14388 | Human | 392517 | Details Get a Quote |
| NCBP3 Knockout HEK293 Cell Line | EDJ-KQ14389 | Human | 55421 | Details Get a Quote |
| LARP1 Knockout HCT 116 Cell Line | EDJ-KQ22935 | Human | 23367 | Details Get a Quote |
| LARP1 Knockout HeLa Cell Line | EDJ-KQ22936 | Human | 23367 | Details Get a Quote |
| IFIT5 Knockout A-549 Cell Line | EDJ-KQ34048 | Human | 24138 | Details Get a Quote |
| IFIT5 Knockout HCT 116 Cell Line | EDJ-KQ34049 | Human | 24138 | Details Get a Quote |
| IFIT5 Knockout HeLa Cell Line | EDJ-KQ34050 | Human | 24138 | Details Get a Quote |
| LARP1B Knockout A-549 Cell Line | EDJ-KQ43934 | Human | 55132 | Details Get a Quote |
| LARP1B Knockout HCT 116 Cell Line | EDJ-KQ43935 | Human | 55132 | Details Get a Quote |
| LARP1B Knockout HeLa Cell Line | EDJ-KQ43936 | Human | 55132 | Details Get a Quote |
Frequently Asked Questions About RNA cap binding
What is RNA cap binding?
RNA cap binding (GO:0000339) is the molecular function of binding to the 7-methylguanosine (m7G) cap at the 5' end of an RNA molecule, a key step in RNA processing, export, and translation.
What genes are involved in RNA cap binding?
Key genes include NCBP1, NCBP2 (nuclear cap-binding complex), EIF4E (cytoplasmic cap-binding protein), and decapping enzymes such as DCP2 and NUDT16.
What is the role of the cap-binding complex (CBC)?
The CBC, composed of NCBP1 and NCBP2, binds the m7G cap on nascent RNA polymerase II transcripts and couples transcription to splicing, export, and translation.
How does eIF4E recognize the mRNA cap?
eIF4E binds the m7G cap through aromatic stacking and hydrogen bonding, recruiting eIF4G and eIF4A to initiate translation.
What diseases are associated with defects in RNA cap binding?
Dysregulation of cap binding is linked to cancer, neurodegeneration, and viral infections. For example, eIF4E overexpression is oncogenic, and viral decapping proteins like OV71 suppress host immunity.
How can CRISPR be used to study RNA cap binding?
CRISPR knockout, point mutation, knock-in, and overexpression models allow researchers to dissect the function of cap-binding genes in RNA processing and disease.
What methods are used to study RNA cap binding?
Common methods include Ribo-seq, RNA-seq, CLIP-seq, polysome profiling, AP-MS, and in vitro binding assays with cap analogs.
What are cap analogs and how are they used?
Cap analogs are synthetic mimics of the m7G cap used for crosslinking, imaging, and therapeutic mRNA design. Photoactivatable cap analogs enable covalent capture of cap-binding proteins.
How is RNA cap binding regulated?
It is regulated by mTOR signaling, the integrated stress response, and cap modifications such as m6Am that alter protein binding.
Why is RNA cap binding important for antiviral immunity?
Interferon-induced proteins like IFIT1 bind cap-related modifications to distinguish self from viral RNA, while viruses encode decapping enzymes to evade detection.
Conclusion
RNA cap binding (GO:0000339) is a fundamental molecular function that governs the fate of RNA polymerase II transcripts. Through the action of the nuclear cap-binding complex, eIF4E, and decapping enzymes, cells coordinate splicing, export, translation, and turnover. Dysregulation of these processes contributes to cancer, neurodegeneration, and viral pathogenesis. Advances in CRISPR-based models and high-throughput methods are enabling precise dissection of cap-binding mechanisms, offering new opportunities for therapeutic intervention.
References
- 1. Kataoka N. 2023. The Nuclear Cap-Binding Complex, a multitasking binding partner of RNA polymerase II transcripts.. J Biochem 175(1):9-15 PMID: 37830942
- 2. Geng J et al.. 2024. Cap-related modifications of RNA regulate binding to IFIT proteins.. RNA 30(10):1292-1305 PMID: 39009378
- 3. Gonatopoulos-Pournatzis T et al.. 2014. Cap-binding complex (CBC).. Biochem J 457(2):231-42 PMID: 24354960
- 4. Sonenberg N. 1988. Cap-binding proteins of eukaryotic messenger RNA: functions in initiation and control of translation.. Prog Nucleic Acid Res Mol Biol 35:173-207 PMID: 3065823
- 5. Whittaker A et al.. 2024. Modeling the structure and DAP5-binding site of the FGF-9 5'-UTR RNA utilized in cap-independent translation.. RNA 30(9):1184-1198 PMID: 38866431
- 6. Cougot N et al.. 2004. 'Cap-tabolism'.. Trends Biochem Sci 29(8):436-44 PMID: 15362228
- 7. Warminski M et al.. 2024. Photoactivatable mRNA 5' Cap Analogs for RNA-Protein Crosslinking.. Adv Sci (Weinh) 11(36):e2400994 PMID: 39049186
- 8. Mthethwa MN et al.. 2025. Biochemical and functional characterization of orf virus decapping protein OV71.. Virol J 22(1):407 PMID: 41310643
